ArticleNature chemical biology2026
Expanding the repertoire of chemically induced covalent neoantigens.
Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ubiquitin-proteasome system generates peptide fragments that are displayed on class I major histocompatibility complex molecules. Hapten-modified peptides, or covalent neoantigens, arise from proteins covalently modified by small molecules and have long been proposed as components of a mechanism for immune recognition. Here we report a platform to investigate this mechanism and harness covalent neoantigens for immune cell recruitment and activation. Using cysteine-reactive probes, we demonstrated that covalently modified intracellular proteins could be processed and presented as covalent neoantigens in multiple cell lines. Immunopeptidomics confirmed the presence of probe-modified peptides within the class I major histocompatibility complex immunopeptidome. We further developed a bioorthogonal strategy for immune cell engagement by combining covalent neoantigens bearing a bioorthogonal handle with complementary immune cell recruiters, leading to activation of CD32- and CD3-expressing reporter immune cells. These findings expand the scope of covalent neoantigen formation and provide a generalizable strategy for immune targeting of covalent neoantigens.
Identifiers
42533153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.